Insights

Here’s why these brokers say the CSL (ASX:CSL) share price might be overcooked

CSL is under the microscope again…
The post Here’s why these brokers say the CSL (ASX:CSL) share price might be overcooked appeared first on The Motley Fool Australia. –

The CSL Limited (ASX: CSL) share price got through the week unscathed, closing on Friday 1% higher to $315.50.

Shares in the global biotechnology company have now recovered to 3-month highs after slipping off the cliff-face back in September. Their investors gave up $26 a share in the course of a week, amid a wide selloff in the ASX 200 healthcare sector.

Whereas the S&P/ASX 200 Health Care index (ASX: XHJ) has gained around 5% this past month, the CSL share price has climbed 7%, with just one slight hiccup along the way.

Both have soared well past the benchmark S&P/ASX 200 Index (ASX: XJO)’s gain of just 0.2% at the time of writing.

CSL share price vs S&P/ASX 200 Health Care index YTD

Source: Google Finance. Google and the Google logo are registered trademarks of Google LLC, used with permission.

CSL is one of Australia’s success stories. Established over a century ago, it now labels itself as a biotechnology leader, with a dynamic portfolio of life-saving products and a reputation for putting patients first.

So with that in mind, let’s take a closer look at what the experts are saying about the outlook for CSL investors.

Blood plasma problems?

CSL is one of only a handful of large plasma collection companies in the world, and the bolus of its revenue comes from collecting blood plasma out of the United States.

In fact, in late October it was announced the company opened its 300th US plasma centre through its subsidiaries there.

Plasma donations are essential to modern-day medicine. They are used to produce therapies in a number of rare disorders. They are used in therapies for immunodeficiency, respiratory conditions, neurological disorders, and bleeding disorders such as haemophilia.

During the pandemic, plasma collection suffered a hit across the globe, due to government-enforced lockdowns in several countries.

The US in particular saw a massive decline, which had a flow-on effect for CSL due to its exposure there.

Fast forward to May 2021, where CSL was forced to increase the amount of cash it pays plasma donors in the US after collection volumes continued to fall sharply.

CSL’s US competitor Haemonetics Corporation (NYSE: HAE) recently lowered its own plasma-grown guidance for the upcoming year as well. As such, CSL’s plasma collection forecasts might be slightly overly optimistic, according to the team at Morgan Stanley.

What are the experts saying?

The investment bank notes it is modelling a 32% increase in quarterly plasma collections at CSL. However, it thinks the forecasts might be a bit top-heavy given Haemonetics’ result.

It reckons this could be a threat to CSL’s revenue in FY23, given the time gap between cash receipts for plasma collection and the end product. Haemonetics also noted the “delay in the acceleration of plasma collections in the quarter” in its earnings call.

Morgan Stanley notes although “it’s early days, and collection trends appear volatile, recent data points could suggest at least some risk”. It has a $280 price target on CSL shares.

Analysts at JP Morgan agree. It notes Haemonetics’ results fell well short of internal estimates, and this poses a risk to earnings estimates on CSL.

The firm also notes that respiratory and COVID-19 infections are on the rise again in Europe and South East Asia. It says the “Immunisation Colonisation is predicting a tough flu season next year for Australia as international travel resumes and COVID-19 restrictions are eased”. Most of CSL’s vaccine revenue comes from “Northern Hemisphere flu season”, it notes.

Researchers at both firms are reserved on CSL. Each of the investment banks believes Haemonetics’ results could spell a slower recovery in plasma collection to pre-COVID levels.

Morgan Stanley values CSL at $280/share, whereas JP Morgan has a slightly higher valuation of $285/share. Each holds an equal weight and neutral rating respectively.

What’s the sentiment on CSL’s share price?

Of the 17 brokers covering CSL, there are 9 that recommend the share as a buy or are bullish on the direction of its share price.

This has remained fairly consistent over the past 2-year period. However, it is sitting below the number back in April and May of this year.

So far this month, CSL is gaining ground once again. It is up again for the month and is beating each of the broad indices.

CSL winning the race this past month

Source: Google Finance. Google and the Google logo are registered trademarks of Google LLC, used with permission.

The average price target is $316 from the group, implying an upside potential of around 0.16% on Friday’s closing price.

However, the spread between the highest and lowest price targets is $72 per share, or 25%. Morgan Stanley and JP Morgan are each the most reserved on the CSL share price with respect to their group’s valuation.

The post Here’s why these brokers say the CSL (ASX:CSL) share price might be overcooked appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

2 outstanding blue chip ASX shares to buy this month

Can CSL (ASX:CSL) shares regain their pre-COVID highs above $330?

Why has the CSL (ASX:CSL) share price fallen over $7 in a week?

3 ASX 200 shares with major competitive advantages

Lockdowns are easing, but are CSL (ASX:CSL) shares out of the woods yet?

The  author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!